EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinicopathological Features of DLL3 Expression and T‐Cell Infiltration in LCNEC : Insights From Pathology and Clinical Response to Tarlatamab

Shotaro Kaneko, Naoki Furuya iD, Yoshihisa Sugiura iD, Hajime Tsuruoka iD, Kazuhiro Nishiyama iD, Honoka Morita, Tomoki Okura, Hisashi Saji iD, Junki Koike iD, Nobuyuki Ohike iD, Masamichi Mineshita iD

Thoracic Cancer · 2026-10 · 17 (20)

DOI: 10.1111/1759-7714.70400 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thoracic Cancer, online erschienen am 15.10.2026. Verfasst von Shotaro Kaneko und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan. Hauptthemen laut MEDLINE: Membrane Proteins, Intracellular Signaling Peptides and Proteins, Lymphocytes, Tumor-Infiltrating, Carcinoma, Neuroendocrine. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Large cell neuroendocrine carcinoma (LCNEC) is a rare and aggressive lung neuroendocrine neoplasm with poor prognosis. Recently, DLL3‐targeted bispecific T‐cell engagers (BiTEs) have shown promising efficacy in small cell lung cancer, and clinical trials are ongoing in LCNEC. This study evaluated DLL3 expression and CD8+ tumor‐infiltrating lymphocytes (TILs) infiltration in LCNEC and investigated their clinical significance and association with tarlatamab efficacy.

Methods

We retrospectively reviewed consecutive patients who were diagnosed with LCNEC. Immunohistochemical analyses for DLL3 and CD8 were performed. DLL3 positivity was defined as staining in ≥ 1% of tumor cells. CD8+ TIL infiltration was graded as low, moderate, or high.

Results

Among 77 screened LCNEC cases, 44 were eligible for analysis. The median age was 75 years. DLL3 expression was observed in 70.5% of cases and was associated with worse survival. Low CD8+ TIL infiltration was observed in 59.1% of cases. Patients with high CD8+ TIL infiltration demonstrated significantly longer survival than those with low infiltration ( p = 0.03). Among representative clinical cases, a patient with DLL3 (+)/CD8 TILs (−) LCNEC achieved marked tumor shrinkage, whereas a patient with DLL3 (−)/CD8 TILs (−) LCNEC showed no response.

Conclusions

DLL3 is frequently expressed in LCNEC and correlates with a poorer prognosis. A majority of LCNEC cases are immunologically characterized as cold tumors lacking CD8+ TILs, which contributes to unfavorable clinical outcomes. Tarlatamab induced a robust antitumor response even in a DLL3 (+) cold tumor. DLL3‐BiTE represents a promising therapeutic strategy for DLL3 (+) LCNEC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Membrane ProteinsIntracellular Signaling Peptides and ProteinsLymphocytes, Tumor-InfiltratingCarcinoma, NeuroendocrineLung NeoplasmsCarcinoma, Large CellHumansFemaleMaleAgedPrognosisRetrospective StudiesAged, 80 and overMiddle AgedCD8-Positive T-LymphocytesAntibodies, Bispecific

Stichwörter der Autor:innen

CD8DLL3T‐cell infiltrationbispecific T‐cell engagertarlatamab

Substanzen

DLL3 protein, humanMembrane ProteinsIntracellular Signaling Peptides and ProteinsAMG 757Antibodies, Bispecific

Autor:innen und Institutionen

  • Department of Respiratory Medicine, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan.
  • Division of Molecular Pathology, Department of Pathology, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan.
  • Department of Thoracic Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan.
  • Department of Pathology, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan.

ORCID-Profile: Naoki Furuya, Yoshihisa Sugiura, Hajime Tsuruoka, Kazuhiro Nishiyama, Hisashi Saji, Junki Koike, Nobuyuki Ohike, Masamichi Mineshita

Zitieren

APA

Kaneko, S., Furuya, N., Sugiura, Y., Tsuruoka, H., Nishiyama, K., Morita, H., Okura, T., Saji, H., Koike, J., Ohike, N., & Mineshita, M. (2026). Clinicopathological Features of DLL3 Expression and T‐Cell Infiltration in LCNEC : Insights From Pathology and Clinical Response to Tarlatamab. Thoracic Cancer, 17(20). https://doi.org/10.1111/1759-7714.70400

Vancouver

Kaneko S, Furuya N, Sugiura Y, Tsuruoka H, Nishiyama K, Morita H, et al. Clinicopathological Features of DLL3 Expression and T‐Cell Infiltration in LCNEC : Insights From Pathology and Clinical Response to Tarlatamab. Thoracic Cancer. 2026;17(20). doi:10.1111/1759-7714.70400

BibTeX
@article{Kaneko2026,
  author = {Kaneko, Shotaro and Furuya, Naoki and Sugiura, Yoshihisa and Tsuruoka, Hajime and Nishiyama, Kazuhiro and Morita, Honoka and Okura, Tomoki and Saji, Hisashi and Koike, Junki and Ohike, Nobuyuki and Mineshita, Masamichi},
  title = {Clinicopathological Features of DLL3 Expression and T‐Cell Infiltration in LCNEC : Insights From Pathology and Clinical Response to Tarlatamab},
  journal = {Thoracic Cancer},
  year = {2026},
  volume = {17},
  number = {20},
  doi = {10.1111/1759-7714.70400}
}
Kostenlos starten →